Chemoinformaics analysis of 10,11-(E)-6-Oxo-Dihydroatlantone
| Molecular Weight | 234.339 | nRot | 4 |
| Heavy Atom Molecular Weight | 212.163 | nRig | 7 |
| Exact Molecular Weight | 234.162 | nRing | 1 |
| Solubility: LogS | -3.093 | nHRing | 0 |
| Solubility: LogP | 3.341 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 39 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 17 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 41.3234 |
| nHD | 0 | BPOL | 23.8066 |
| QED | 0.841 |
| Synth | 2.729 |
| Natural Product Likeliness | 0.824 |
| NR-PPAR-gamma | 0.071 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.512 |
| Pgp-sub | 0.004 |
| HIA | 0.003 |
| CACO-2 | -4.589 |
| MDCK | 0.0000234 |
| BBB | 0.562 |
| PPB | 0.886489 |
| VDSS | 1.712 |
| FU | 0.103049 |
| CYP1A2-inh | 0.736 |
| CYP1A2-sub | 0.886 |
| CYP2c19-inh | 0.881 |
| CYP2c19-sub | 0.789 |
| CYP2c9-inh | 0.84 |
| CYP2c9-sub | 0.963 |
| CYP2d6-inh | 0.209 |
| CYP2d6-sub | 0.784 |
| CYP3a4-inh | 0.391 |
| CYP3a4-sub | 0.376 |
| CL | 15.6 |
| T12 | 0.719 |
| hERG | 0.012 |
| Ames | 0.037 |
| ROA | 0.063 |
| SkinSen | 0.167 |
| Carcinogencity | 0.156 |
| EI | 0.949 |
| Respiratory | 0.285 |
| NR-Aromatase | 0.022 |
| Antiviral | Yes |
| Prediction | 0.922737 |